1.Solitary fibrous tumor of the lesser omentum mimicking stomach gastrointestinal stromal tumor
Seonghoon KIM ; Jaehyuk HEO ; Pyungsu KIM ; Hyeseung HAN ; Hoyoon BANG
Korean Journal of Clinical Oncology 2020;16(2):142-144
Solitary fibrous tumor (SFT) is a mesenchymal tumor that rarely occurs in the abdomen. We report a very rare case of an abdominal SFT in the lesser omentum. A 39-year-old Korean man was referred to our center for management of a 9 cm incidental mass in the abdominal space found on a chest computed tomography (CT) during a routine medical examination. He had no symptoms, and there were no specific findings on physical examination. A contrast enhancement CT was performed, and an extraluminal gastrointestinal stromal tumor in the stomach or a pancreatic origin mass was suspected. Surgery was performed and an enclosed mass in the lesser omentum was observed, which was resected completely. The postoperative course was uneventful. Based on microscopy, the omental tumor was diagnosed as SFT.
2.Solitary fibrous tumor of the lesser omentum mimicking stomach gastrointestinal stromal tumor
Seonghoon KIM ; Jaehyuk HEO ; Pyungsu KIM ; Hyeseung HAN ; Hoyoon BANG
Korean Journal of Clinical Oncology 2020;16(2):142-144
Solitary fibrous tumor (SFT) is a mesenchymal tumor that rarely occurs in the abdomen. We report a very rare case of an abdominal SFT in the lesser omentum. A 39-year-old Korean man was referred to our center for management of a 9 cm incidental mass in the abdominal space found on a chest computed tomography (CT) during a routine medical examination. He had no symptoms, and there were no specific findings on physical examination. A contrast enhancement CT was performed, and an extraluminal gastrointestinal stromal tumor in the stomach or a pancreatic origin mass was suspected. Surgery was performed and an enclosed mass in the lesser omentum was observed, which was resected completely. The postoperative course was uneventful. Based on microscopy, the omental tumor was diagnosed as SFT.
3.Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jung Hee KIM ; Dong Hyun SINN ; Kyunga KIM ; Hyeseung KIM ; Geum Youn GWAK ; Yong Han PAIK ; Moon Seok CHOI ; Joon Hyeok LEE ; Kwang Cheol KOH ; Seung Woon PAIK
Gut and Liver 2016;10(6):939-947
BACKGROUND/AIMS: Antiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in HBV-related HCC is not clear. METHODS: A retrospective cohort of 451 newly diagnosed, HBV-related HCC patients without antiviral therapy at diagnosis, who started antiviral therapy with either entecavir (n=249) or lamivudine (n=202), were enrolled. RESULTS: The median survival was longer for the entecavir group than for the lamivudine group, and lamivudine use (vs entecavir) was an independent factor for mortality (hazard ratio [HR], 1.49; p=0.002). Lamivudine use (vs entecavir) was an independent risk factor for new-onset hepatic decompensation (HR, 1.67; p=0.010) in 318 patients without previous hepatic decompensation, and it was also an independent risk factor for recurrence after curative therapy (HR, 1.84; p=0.002) in 117 patients who received curative therapy. The findings were similar in a propensity score-matched cohort. CONCLUSIONS: Overall survival, decompensation-free survival, and recurrence-free survival were better in the entecavir-treated patients than in the lamivudine treated-patients, indicating that the potent antiviral drug should be the preferred choice in HBV-related HCC patients.
Antiviral Agents
;
Carcinoma, Hepatocellular*
;
Cohort Studies
;
Diagnosis
;
Hepatitis B virus
;
Hepatitis B*
;
Hepatitis B, Chronic
;
Hepatitis*
;
Humans
;
Lamivudine*
;
Mortality
;
Recurrence
;
Retrospective Studies
;
Risk Factors
4.Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jung Hee KIM ; Dong Hyun SINN ; Kyunga KIM ; Hyeseung KIM ; Geum Youn GWAK ; Yong Han PAIK ; Moon Seok CHOI ; Joon Hyeok LEE ; Kwang Cheol KOH ; Seung Woon PAIK
Gut and Liver 2016;10(6):939-947
BACKGROUND/AIMS: Antiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in HBV-related HCC is not clear. METHODS: A retrospective cohort of 451 newly diagnosed, HBV-related HCC patients without antiviral therapy at diagnosis, who started antiviral therapy with either entecavir (n=249) or lamivudine (n=202), were enrolled. RESULTS: The median survival was longer for the entecavir group than for the lamivudine group, and lamivudine use (vs entecavir) was an independent factor for mortality (hazard ratio [HR], 1.49; p=0.002). Lamivudine use (vs entecavir) was an independent risk factor for new-onset hepatic decompensation (HR, 1.67; p=0.010) in 318 patients without previous hepatic decompensation, and it was also an independent risk factor for recurrence after curative therapy (HR, 1.84; p=0.002) in 117 patients who received curative therapy. The findings were similar in a propensity score-matched cohort. CONCLUSIONS: Overall survival, decompensation-free survival, and recurrence-free survival were better in the entecavir-treated patients than in the lamivudine treated-patients, indicating that the potent antiviral drug should be the preferred choice in HBV-related HCC patients.
Antiviral Agents
;
Carcinoma, Hepatocellular*
;
Cohort Studies
;
Diagnosis
;
Hepatitis B virus
;
Hepatitis B*
;
Hepatitis B, Chronic
;
Hepatitis*
;
Humans
;
Lamivudine*
;
Mortality
;
Recurrence
;
Retrospective Studies
;
Risk Factors
5.Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters.
Jin Hee SOHN ; Mee Yon CHO ; Yangsoon PARK ; Hyunki KIM ; Woo Ho KIM ; Joon Mee KIM ; Eun Sun JUNG ; Kyoung Mee KIM ; Jae Hyuk LEE ; Hee Kyung CHAN ; Do Youn PARK ; Mee JOO ; Sujin KIM ; Woo Sung MOON ; Mi Seon KANG ; So Young JIN ; Yun Kyung KANG ; Sun Och YOON ; Hyeseung HAN ; Eunhee CHOI
Cancer Research and Treatment 2015;47(4):813-822
PURPOSE: In 2010, the World Health Organization categorized L-cell type neuroendocrine tumors (NETs) as tumors of uncertain malignancy, while all others were classified as malignant. However, the diagnostic necessity of L-cell immunophenotyping is unclear, as are tumor stage and grade that may guide diagnosis and management. To clarify the predictive markers of rectal neuroendocrine neoplasms (NENs), 5- and 10-year overall survival (OS) was analyzed by pathological parameters including L-cell phenotype. MATERIALS AND METHODS: A total of 2,385 rectal NENs were analyzed from our previous multicenter study and a subset of 170 rectal NENs was immunophenotyped. RESULTS: In univariate survival analysis, tumor grade (p < 0.0001), extent (p < 0.0001), size (p < 0.0001), lymph node metastasis (p=0.0063), and L-cell phenotype (p < 0.0001) showed significant correlation with the prognosis of rectal NENs; however, none of these markers achieved independent significance in multivariate analysis. The 10-year OS of tumors of NET grade 1, < 10 mm, the mucosa/submucosa was 97.58%, 99.47%, and 99.03%, respectively. L-Cell marker, glucagon II (GLP-1&2), with a cut off score of > 10, is useful in defining L-Cell type. In this study, an L-cell immunophenotype was found in 83.5% of all rectal NENs and most, but not all L-cell type tumors were NET G1, small (< 10 mm) and confined to the mucosa/submucosa. CONCLUSION: From these results, the biological behavior of rectal NENs does not appear to be determined by L-cell type alone but instead by a combination of pathological parameters.
Diagnosis
;
Glucagon
;
Immunohistochemistry
;
Immunophenotyping
;
International Classification of Diseases
;
Lymph Nodes
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Neuroendocrine Tumors*
;
Phenotype
;
Prognosis
;
Rectal Neoplasms
;
World Health Organization